Company: CERO
Filing Date: 2025-07-02
Form Type: 424B3
Source: 0001213900-25-061023
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-02
Form: 424B3
Chunk 2
---
 registered pursuant to Section 12(b) of the Act:</div>

| Title of each class                                                                  |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, $0.0001 par value per share                                            |     | CERO              |     | Nasdaq Capital Market                     |
| Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock |     | CEROW             |     | Nasdaq Capital Market                     |

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into Material Definitive Agreement.

On June 25, 2025, CERo Therapeutics Holdings,
Inc. (the “Company”) entered into an amendment (the “Amendment”) to the securities purchase agreement (as amended,
the “Securities Purchase Agreement”) dated as of April 21, 2025, pursuant to which the Company added certain new institutional
investors (the “New Investors”) to the schedule of buyers in the Securities Purchase Agreement, to issue and sell to such
New Investors, in one or more closings shares of the Company’s Series D convertible preferred stock, par value $0.0001 per share
(the “Series D Preferred Stock”).

The description of the terms and conditions of the Amendment does not
purport to be complete and is qualified in its entirety by the full text of the form of Amendment, which is filed as Exhibit 10.2 hereto.

Item 3.02 Unregistered Sales of Equity Securities.

As previously reported on the Current Report on
Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 22, 2025, the Company entered into the Securities
Purchase Agreement on April 21, 2025 with certain institutional investors (the “Investors”), pursuant to which the Company
agreed to issue and sell, in one or